Arungarinathan, G., McKay, G. A. and Fisher, M. (2011) Drugs for diabetes: part 4 acarbose. British Journal of Cardiology, 18(2), pp. 78-81.
Full text not currently available from Enlighten.
Publisher's URL: http://bjcardio.co.uk/2011/04/drugs-for-diabetes-part-4-acarbose/
Abstract
Acarbose is an alpha-glucosidase inhibitor acting in the gastrointestinal tract producing modest reductions in postprandial hyperglycaemia, with negligible risk of hypoglycaemia and weight gain. In a subgroup of the United Kingdom Prospective Diabetes Study (UKPDS), acarbose showed glycaemic benefits irrespective of the type of concomitant therapy. Acarbose was shown to produce a significant reduction in the progression to diabetes in patients with impaired glucose tolerance in the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial, and in a post-hoc analysis of STOP-NIDDM a reduction in cardiovascular events was observed. Gastrointestinal side effects are the main limiting factor in clinical practice, leading to high rates of non-compliance and discontinuation.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | McKay, Dr Gerard |
Authors: | Arungarinathan, G., McKay, G. A., and Fisher, M. |
College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
Journal Name: | British Journal of Cardiology |
Journal Abbr.: | Br J Cardiol |
Publisher: | MediNews Limited |
ISSN: | 0969-6113 |
ISSN (Online): | 1753-4313 |
University Staff: Request a correction | Enlighten Editors: Update this record